Consumer goods company Reckitt Benckiser Group Plc (RB.L, RBGPF.PK) posted 7% higher first-quarter total net revenue of 2.52 billion pounds, with like-for-like sales also rising 7%. Like-for-like net revenue growth, excluding RB Pharmaceuticals or RBP, was 6%.
Looking forward, the company said it remains confident of achieving its full-year targets of +5-6% total net revenue growth, excluding RBP at constant exchange rates, while maintaining operating margins.
Reckitt Benckiser's Chief Executive said, "We are pleased with a strong start to the year, with our Health and Hygiene brands leading RB's growth across all geographies. Growth was driven from a combination of innovations, increased Brand Equity Investments and better in market executions. Mucinex and Strepsils have done particularly well, benefitting from a higher incidence of flu in the US and Cold, Flu and Sinus innovations. Nurofen and Durex also had a strong performance. In Hygiene, Dettol continues to grow very strongly in Emerging Market Areas through innovation and category expansion, and Lysol is performing well in the US."
For comments and feedback: editorial@rttnews.com